November 2026

Press Releases & News

FORT LEE, N.J., Nov. 3 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced that lirafugratinib (Lyrfigtu™) has been added

Read more